Zogenix Inc.'s investigational drug, ZX008, received the U.S. Food and Drug Administration's breakthrough therapy designation to treat a rare form of epilepsy.
The designation is based on the results of a phase 3 trial that showed the drug was superior in treating seizures in children and young adults suffering from the Dravet syndrome.
Dravet syndrome is a type of epilepsy with seizures that are often triggered by hot temperatures or fever.
The designation is intended to expedite the development and review of the medicine.
The drug is considered an orphan drug in both the U.S. and Europe. It has also received the fast track designation in the U.S.
Emeryville, Calif.-based Zogenix is focused on developing therapies for patients with rare central nervous system conditions.
